A cross-reacting material CRM197 conjugate vaccine induces diphtheria toxin neutralizing antibody response in children and adolescents infected or not with HIV

• Published in: Vaccine Vol. 35; no. 31; pp. 3803 - 3807
• Main Authors: Silva, Giselle P., Santos, Rafaela S., Pereira-Manfro, Wânia F., Ferreira, Bianca, Barreto, Daniella M., Frota, Ana Cristina C., Hofer, Cristina B., Milagres, Lucimar G.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 05.07.2017
• Subjects: adolescents; Allergy and Immunology; Bactericidal antibody; children; Conjugate vaccine; CRM197; Diphtheria neutralizing antibody; herd immunity; Human immunodeficiency virus; neutralization; neutralizing antibodies; patients; serotypes; vaccination; vaccines; HI; DTP; Conjugate vaccine; MenC; CRM197; DT-Nab; MTT; Bactericidal antibody; SBA; Diphtheria neutralizing antibody; HC; V1; V2; V3; V4; HAART; before immunization; brometo de [3-(4,5-dimetiltiazol-2yl)-2,5-difenil tetrazolium]; one-two months after first dose; serum bactericidal antibody; CRM 197; one year after first dose; highly active antiretroviral therapy; healthy controls; diphtheria-tetanus-pertussis; cross-reacting material; one-two months after booster; diphtheria toxin neutralizing antibody; HIV-infected children/adolescents; serogroup C meningococcus
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2017.05.080

Anti-diphtheria antibody levels decrease with aging, and frequent booster vaccinations are required to maintain herd immunity. We analyzed the diphtheria toxin neutralizing antibody (DT-Nab) response induced by a conjugate vaccine (meningococcal C polysaccharide-CRM197) in HIV-vertically infected (HI) children and adolescents and healthy controls (HC) with matched age. We report the association of DT-Nab with the bactericidal antibodies to serogroup C meningococcus (MenC). Before vaccination, 21 HI patients (50%) had no protection against diphtheria (≤0.01IU/ml of antibody) and only 8 (19%) showed complete protection (≥0.1IU/ml). About half of the HC (56%) had complete protection before immunization and 6 subjects (12%) had no protection against diphtheria. After one and two vaccine injections, 96% of HC and 64% of HI vaccinees, respectively, showed full protection against diphtheria. These data indicate that CRM197 was able to induce primary and/or booster response in both groups of individuals.